In January of this year, Biostone was delighted to receive MDSAP certification from BSI.

Undergoing the MDSAP (Medical Device Single Audit Program) was Biostone’s main goal for 2022. Receiving certification shows that Biostone has shown compliance with the standards and regulatory requirements of five different medical device markets including: Australia, Brazil, Canada, Japan and the United States. 

We are proud of the team for successfully fulfilling the extensive process to achieve this.

For 2023, we are currently, and looking to expand, working partnerships within these territories to bring si-Mochi to their medical device markets in the future. 

If you are interested in learning more about Biostone and our goals, or are interested in distribution, please visit our contact page. 

Want to learn more about our product si-Mochi? Visit here.

We will be at AAOS 2023 – Booth 5945 in Las Vegas if you would like to meet us in person.